Статья

Experience with the use of recombinant humanized monoclonal antibodies to the human receptor for interleukin-6 in patients with CoVID-19 [оПыт ПримеНеНия рекомбиНаНтНоГо ГумаНизироваННоГо моНоклоНальНоГо аНтитела к человечеСкому рецеПтору иНтерлейкиНа-6 у ПациеНтов С COVID-19]

D. Gusev, M. Vashukova, I. Feduniak, V. Musatov, V. Kapatsyna,
2021

The new coronavirus infection (COVID-19) has become a truly global challenge for all of humanity, and, above all, for the healthcare system. Among its most important aspects requiring careful analysis are the clinical and laboratory features of the course of the disease, which make it possible to determine approaches to pathogenetic therapy in severe forms of the disease. Materials and methods. A retrospective analysis of medical records of patients (n = 31) of severe COVID-19 patients who were hospitalized in St. Petersburg City Clinical Hospital for Infectious Diseases named after S.P. Botkin”in March – May 2020. Clinical and laboratory characteristics were evaluated, including the level of ferritin, C-reactive protein, D-dimer, interleukin-6, depending on the severity of the disease. The criteria for the appointment of a recombinant humanized monoclonal antibody to the human receptor for interleukin-6 (INN – tocilizumab) in patients with a severe course of the disease and its effectiveness are determined. Results. In the treatment of severe patients with COVID-19, it is necessary to carefully evaluate the clinical picture of the course of the disease, which may be ahead of changes in laboratory parameters. The introduction of tocilizumab leads to a rapid regression of general infectious symptoms, subjective and objective manifestations of respiratory failure and, as a consequence, a decrease in the duration of hospitalization. It is extremely important that the drug is administered in a timely manner during the rise of the “cytokine storm”. The time for optimal administration of tocilizumab begins from 8-9 days from the onset of the disease, until the patient is transferred to mechanical ventilation. © 2020 Interregional public organization Association of infectious disease specialists of Saint-Petersburg and Leningrad region (IPO AIDSSPbR). All rights reserved.

Цитирование

Похожие публикации

Документы

Источник

Версии

  • 1. Version of Record от 2021-04-27

Метаданные

Об авторах
  • D. Gusev
    National Medical Research Centre named after V.A. Almazov, Saint-Petersburg, Russian Federation
  • M. Vashukova
    Clinical Infectious Hospital named after S.P. Botkin, Saint-Petersburg, Russian Federation
  • I. Feduniak
    North-Western State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russian Federation
  • V. Musatov
    Saint-Petersburg State University, Saint-Petersburg, Russian Federation
  • V. Kapatsyna
Название журнала
  • Jurnal Infektologii
Том
  • 12
Выпуск
  • 3
Страницы
  • 28-33
Ключевые слова
  • C reactive protein; D dimer; ferritin; interleukin 6; tocilizumab; Article; artificial ventilation; clinical article; coronavirus disease 2019; disease severity; ferritin blood level; human; personal experience; retrospective study
Издатель
  • Interregional public organization Association of infectious disease specialists of Saint-Petersburg and Leningrad region (IPO AIDSSPbR)
Тип документа
  • journal article
Тип лицензии Creative Commons
  • CC
Правовой статус документа
  • Свободная лицензия
Источник
  • scopus